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Version española  
Regulatory agencies approve drugs for marketing when the ratio of risk to benefit of the 
drugs is positive, i.e. the potential benefit of using the drug justifies the risk of drug related 
adverse reactions (ADR). At the point of approval of a drug there is not adequate 
information about all possible negative outcomes arising from its use in clinical practice. 
The information is even more limited for patient subgroups, diseases and treatment 
combinations that were not evaluated in the clinical trials required for approval. Therefore, 
performing post-marketing pharmacoepidemiological studies is necessary for a better 
understanding of drug use in usual clinical practice conditions and the effect of the drugs 
on the general patient population.  
The incidence of ADRs has been considered high. A study pooling the incidence of ADR 
related hospital admissions of multiple studies derived a median of 4.1% ADR related 
hospital admissions in the USA1. Higher ADR related hospital admissions were reported 
among specific subpopulations at risk, e.g. cardiovascular patients1. Another study found 
that 6.5% of all hospitalizations in the UK were related to ADR2. Severe ADRs may lead 
to hospital intensive care unit admission3. The intensive care units also have a higher rate 
of ADRs than other hospital units4. A high incidence of ADRs was also identified in the 
ambulatory setting with an estimated 180.000 life threatening or fatal adverse drug effects 
per year in the USA5.  
The article by Alfonso Orta et al6 is a pharmacoepidemilogic study that presents a series of 
case reports of ADRs identified in the intensive care unit of a Cuban hospital. The study 
identifies streptokinase, a thrombolytic drug used for dissolving blood clots, as the drug 
involved in 61% of the ADRs reported. Problems associated with the safety of 
streptokinase have been known to be caused by its potential antigenicity, short half-life, 
and lack of fibrin specificity7,8. These problems motivated a drastic reduction of 
streptokinase use in the USA.  
Streptokinase is available as a generic drug and its therapeutic alternatives have higher 
cost9. Drug cost is the main reason why streptokinase continues to be used around the world 
in spite of its potential risks, especially in health care systems with fewer resources 
available for health care.  
Rational drug utilization requires consideration of drug cost as a factor in the therapy 
selection decision-making process. But other costs should also be considered in the 
process. Health care costs such as physician visits or hospital care, and not health care costs 
such as informal caregiver time and patient time for treatment should also be considered. 
Consideration of health care costs is especially important when a drug of lower cost may 
generate a higher rate of ADRs that could require expensive hospital care or intensive care.  
While ADRs generate negative health outcomes, costs are also associated with the 
prevention, identification and treatment of these reactions. Hospital care represents an 
important part of the costs of ADRs due to an increase in admissions and in the length of 
stay1,10,11.  
Rational drug utilization requires an evaluation of the risk/benefit ratio and the cost of 
pharmaceuticals. Pharmacoepidemiologic studies of ADRs allow for the identification of 
potential drugs and therapeutic classes where prevention efforts could best improve clinical 
outcomes and/or reduce the costs of those events. The fact that the majority of the ADR 
identified by Alfonso Orta et al6 are related to the use of streptokinase suggests that 
prevention efforts in Cuba should first focus on this drug. Additionally, the cost-benefit of 
streptokinase from the perspective of the Cuban health care system should be assessed.  
Several strategies have been proposed to reduce the incidence of ADRs1,10. These strategies 
include educational activities, risk group identification programs, implementation of 
clinical guidelines, clinical and laboratory monitoring of ADR, and drug safety monitoring. 
Special mention should be given to the need of more pharmacoepidemiologic research, 
such as the one conducted by Alfonso Orta et al6, and more organized 
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